financetom
Business
financetom
/
Business
/
Lululemon Athletica Beats Third-Quarter Views, Lifts Full-Year Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon Athletica Beats Third-Quarter Views, Lifts Full-Year Outlook
Dec 5, 2024 2:09 PM

04:46 PM EST, 12/05/2024 (MT Newswires) -- Lululemon Athletica ( LULU ) late Thursday reported stronger-than-expected fiscal third-quarter results as the athletic apparel and footwear company benefitted from momentum in international markets.

The retailer's earnings per share rose to $2.87 during the three months through Oct. 27 from $1.96 the year before, topping the consensus on FactSet for $2.72. Revenue grew 9% year over year to $2.4 billion, above analysts' $2.36 billion estimate.

Shares were up 7.7% in after-hours trade.

Revenue in the Americas edged 2% higher, while international sales surged 33%.

Comparable sales gained 4% on a yearly basis, as a 2% decline in the Americas was more than offset by a 25% jump in international operations.

For the full year, earnings are now set to come in between $14.08 to $14.16 per share, up from its previous guidance of $13.95 and $14.15. Revenue is pegged at $10.45 billion to $10.49 billion versus prior projections of $10.38 billion to $10.48 billion. The consensus is for GAAP EPS of $13.91 and revenue of $10.45 billion.

Lululemon expects EPS to be in a range of $5.56 to $5.64 for the fourth quarter and revenue of $3.48 billion to $3.51 billion. The Street is looking for GAAP EPS of $5.65 and revenue of $3.5 billion.

The company said its board approved a $1 billion increase to Lululemon's stock repurchase program on Tuesday, taking its remaining authorization to $1.8 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that its experimental ARV-393 showed significant single-agent activity in a certain type of cell lymphoma, based on data from preclinical studies. The results cover activity in patient-derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. When combined with oral...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Jun 13, 2025
07:45 AM EDT, 06/13/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said updated results from 17 patients in its phase 1/2 BEACON trial evaluating BEAM-101, a base-editing therapy for severe sickle cell disease, showed robust and durable increases in fetal hemoglobin, reduced sickle hemoglobin, and normalized hemolysis markers. The company will present the new safety and efficacy data at...
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Friday that initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months. The biopharmaceutical company said navenibart demonstrated an overall attack-freedom of 50% over...
Copyright 2023-2026 - www.financetom.com All Rights Reserved